Sign in Subscribe
Pharmaceutical industry

Isis Pharmaceuticals and Ciba-Geigy Expand Collaboration to Broaden Antisense Research and Development

Strategic Insights

— 1 min read

Isis Pharmaceuticals and Ciba-Geigy Limited have signed a letter of intent to broaden their collaboration in antisense research and development, with a focus on developing therapeutic compounds targeting isotypes of the protein kinase C (PKC) multi-gene family. This collaboration aims to discover additional therapeutic compounds and advance them through development, with Ciba funding the development of both ISIS 3521 and ISIS 5132/CGP 69846A. Isis will receive milestone payments and royalties on sales, while Ciba will market the compounds worldwide. Additionally, Ciba will make an equity investment of $7 million in Isis as part of its current public offering.

Key Takeaways:

  • The collaboration between Isis Pharmaceuticals and Ciba-Geigy Limited has been expanded to include the development of ISIS 3521, an anticancer compound that is a Jan antisense inhibitor of protein kinase C (PKC).
  • The broadened collaboration will focus on discovering additional therapeutic compounds targeting isotypes of the PKC multi-gene family, which are implicated in a range of diseases including cancer and inflammation.
  • Ciba will fund the development of both ISIS 3521 and ISIS 5132/CGP 69846A, while Isis will receive milestone payments and royalties on sales.
  • Ciba will market the compounds worldwide and will make an additional equity investment of $7 million in Isis as part of its current public offering.
  • Isis has three compounds in human clinical trials, including ISIS 2922, ISIS 2105, and ISIS 2302, and several additional compounds in preclinical development.

Statistics:

  • Ciba-Geigy Limited's Pharma Division had sales of SFr. 6,105 million in 1994.
  • The Ciba group had total sales of SFr. 22,049 million in 1994.
  • Isis Pharmaceuticals has three compounds in human clinical trials, with ISIS 2922 in Phase III, ISIS 2105 in Phase II, and ISIS 2302 in Phase II.
  • Isis has several additional compounds in preclinical development.
  • Ciba will fund the development of both ISIS 3521 and ISIS 5132/CGP 69846A.

Sources:

  • Isis Pharmaceuticals press release, September 13, 1995
  • Ciba-Geigy Limited financial report, 1994
  • Prospectus for Isis Pharmaceuticals' public offering, filed with the Securities and Exchange Commission

Read more